论文部分内容阅读
Objective:The aim of our study was to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with previously untreated advanced malignant pleural mesothelioma (MPM). Methods:Thirty-three eligible patients with histologically proven advanced MPM with ECOG PS of ≤ 2 and had adequate liver and kidney functions received gemcitabine (1000 mg/m 2 ) on days 1 and 8 combined with cisplatin (80 mg/m 2 ) on day 1. Results:The majority of the study group were males and constituted 87.9% (n = 29), while females constituted 12.1% (n = 4). The median age was 52 years and ranged from 37 to 69 years. Regarding SWOG performance status, 5 patients were PS 0, 21 patients were PS 1 and 7 patients were PS 2. Regarding pathological subtypes, epithelial histology represented 84.8% of the study (n = 28) while sarcomatoid type represented 6% (n = 2) and biphasic type accounted for 9% (n = 3). Regarding staging according to IMIG staging system, 12.1% of patients were stage II, 54.5% were stage III and 33.3% were stage IV. Only one patient (3%) had attained a complete response, 18 patients (54.5%) showed partial response, 12 patients (36.4%) showed stationary disease, while 2 patients (6.1%) showed progressive disease. The correlation between response rate obtained and PS was statistically significant (P = 0.029). After a median follow-up of 14.4 months, the median survival time was 20.3 months (95% CI:14.58-26.01 months) and the progression free survival time was 11.8 months (95% CI:10.76-12.83 months) Conclusion:The combination of gemcitabine and cisplatin is an active and safe treatment in patients with MPM. Further larger comparative studies are warranted to document this finding.
Objective: The aim of our study was to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with previously untreated advanced malignant pleural mesothelioma (MPM). Methods: Thirty-three eligible patients with histologically proven advanced MPM with ECOG PS of ≤ 2 and had adequate liver and kidney functions received gemcitabine (1000 mg / m 2) on days 1 and 8 combined with cisplatin (80 mg / m 2) on day 1. Results: The majority of the study group were males and 87.9% (n = 29), while females constituted 12.1% (n = 4). The median age was 52 years and ranged from 37 to 69 years. Regarding SWOG performance status, 5 patients were PS 0, 21 patients were PS 1 and 7 patients were PS 2. Regarding pathological subtypes, epithelial histology represented 84.8% of the study (n = 28) while sarcomatoid type represented 6% (n = 2) and biphasic type accounted for 9% (n = 3). Regarding staging according to IMIG staging system , 12.1% of patients were stage II, 54.5% were st Only one patient (3%) had attained a complete response, 18 patients (54.5%) showed partial response, 12 patients (36.4%) showed stationary disease, while 2 patients (6.1%) showed After a median follow-up of 14.4 months, the median survival time was 20.3 months (95% CI: 14.58-26.01 months) and the progression (P = 0.029) free survival time was 11.8 months (95% CI: 10.76-12.83 months) Conclusion: The combination of gemcitabine and cisplatin is an active and safe treatment in patients with MPM. Further larger comparative studies are warranted to document this finding.